Low-dose endotoxin elicits variability in the inflammatory response in healthy volunteers.

Endotoxin has been implicated as a cause of sepsis, inflammation and organ dysfunction after surgery. Patients differ in their response to endotoxin, and this may account for differences in outcome. The traditional human model of endotoxin challenge (2-4 ng/kg) is not associated with significant inter-individual variability in systemic inflammation and may not be suitable for studying variability in the inflammatory response. We examined whether low-dose regimens of endotoxin cause significant variability in inflammation. Volunteers (n = 30) were randomised in a double-blinded ('double-dummy') study to one of 6 dosing regimens: saline (placebo) or Escherichia coli O:113 endotoxin as a 4 ng/kg bolus (positive control), 0.25 ng/kg (bolus), 0.25 ng/kg (30 min infusion), 0.75 ng/kg (bolus) or 0.75 ng/kg (30 min infusion). Temperature, white cell count, platelet count, C-reactive protein and cytokine changes from baseline were measured. In contrast to subjects receiving placebo, those randomised to 4 ng/kg endotoxin exhibited significant systemic inflammation during the 10-h observation period. The four low-dose regimens elicited variability in most markers of inflammation. We conclude that low-dose endotoxin elicits inter-individual variability in inflammation and could be used to test factors that may affect the human response to endotoxin.

[1]  S. Opal The clinical relevance of endotoxin in human sepsis: a critical analysis , 2002, Journal of endotoxin research.

[2]  H. Harris,et al.  Endogenous lipoproteins impact the response to endotoxin in humans , 2002, Critical care medicine.

[3]  C. Bodian,et al.  Endotoxin-neutralizing capacity of serum from cardiac surgical patients. , 2001, Journal of cardiothoracic and vascular anesthesia.

[4]  T. Pollmächer,et al.  Effects of Sleep on Endotoxin-Induced Host Responses in Healthy Men , 2001, Psychosomatic medicine.

[5]  D. Reich,et al.  Decreased Endotoxin Immunity Is Associated with Greater Mortality and/or Prolonged Hospitalization after Surgery , 2001, Anesthesiology.

[6]  J. Parrillo,et al.  A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia , 2000, Critical Care Medicine.

[7]  H. D. Hochstein,et al.  Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. , 1999, The Journal of infectious diseases.

[8]  H. Eichler,et al.  Effects of Endotoxemia on Thrombopoiesis in Men , 1999, Thrombosis and Haemostasis.

[9]  W. White,et al.  Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. , 1997, JAMA.

[10]  T. van der Poll,et al.  Release of bactericidal/permeability-increasing protein in experimental endotoxemia and clinical sepsis. Role of tumor necrosis factor. , 1996, Journal of immunology.

[11]  M. Boermeester,et al.  Effect of hypertriglyceridemia on endotoxin responsiveness in humans , 1995, Infection and immunity.

[12]  S. Calvano,et al.  Influence of IL-1 receptor blockade on the human response to endotoxemia. , 1995, Journal of immunology.

[13]  A. Webb,et al.  The role of endotoxin immunity, neutrophil degranulation and contact activation in the pathogenesis of post-operative organ dysfunction. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[14]  D. Wilmore,et al.  Effects ofin vivo endotoxin infusions onin vitro cellular immune responses in humans , 1992, Journal of Clinical Immunology.

[15]  K. Tracey,et al.  Peripheral blood leukocyte kinetics following in vivo lipopolysaccharide (LPS) administration to normal human subjects. Influence of elicited hormones and cytokines. , 1989, Annals of surgery.

[16]  G. Csako,et al.  Response of humans to gamma-irradiated reference Escherichia coli endotoxin. , 1989, Journal of clinical & laboratory immunology.

[17]  A. Cerami,et al.  Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.

[18]  F. Audibert,et al.  Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. , 1981, The Journal of infectious diseases.

[19]  E. Rackow,et al.  Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial. , 1995, Critical care medicine.